Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: Feasibility and efficacy

British Journal of Cancer

Volumn 85, Issue 10, 2001, Pages 1456-1461

  Huisman, C ^a   Biesma, B ^b   Postmus, P E ^a   Giaccone, G ^a   Schramel, F M N H ^c   Smit, E F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Chemotherapy; Cisplatin; Epirubicin; Non small cell lung cancer; Second line

Indexed keywords

CISPLATIN; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEASIBILITY STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035900810     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2013     Document Type: Article

References (21)

1. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer
2. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: A phase II study
3. Phase I-II study of high-dose epirubicin in advanced non-small cell lung cancer
4. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with non-small cell lung cancer previously treated with platinum-containing chemotherapy
5. Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgastrim in advanced breast cancer
6. Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small cell lung cancer
7. Second-line chemotherapy in relapsing or refractory non-small cell lung cancer patients - A review
8. Phase II clinical trial of epirubicin in advanced squamous, adeno-and large cell carcinoma of the lung
9. Phase II trial of 4′-epidoxombicin in patients with non-small cell lung cancer
10. Dose-dense epirubicin and paclitaxel with G-CSF: A study of decreasing intervals in metastatic breast cancer
11. 4′-epidoxorubicin and cisdiamminedichloroplatinum in advanced non-small cell bronchogenic carcinoma: A phase II study
12. A phase II clinical trial of 4′-epidoxorubicin in advanced solid tumours
13. Activity of high-dose epirubicin in advanced non-small cell lung cancer
14. A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small cell lung cancer
15. Multicenter randomized clinical trial on high-dose epirubicin plus cisplatinum versus vinorelbine plus cisplatinum in advanced non-small cell lung cancer
16. Epirubicin in non-oat cell lung cancer-response rates and the importance of immunopathology: A northern California oncology group study
17. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized trials
18. Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate
19. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
20. A phase II study of high dose epirubicin in unresectable non small cell lung cancer
21. Phase II study of high dose epirubicin in non-small cell lung cancer